The use of androgens in menopause

Clinical Obstetrics and Gynecology

Volumn 42, Issue 4, 1999, Pages 883-894

  Hoeger, Kathleen M ^a,b   Guzick, David S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRATEST; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLTESTOSTERONE; PRASTERONE; TESTOSTERONE DERIVATIVE;

ACNE; ANDROGEN THERAPY; CONFERENCE PAPER; DIET SUPPLEMENTATION; FEMALE; HEADACHE; HIRSUTISM; HUMAN; MASTALGIA; MENOPAUSE; OVARIECTOMY; PATIENT SELECTION; POSTMENOPAUSE; VIRILIZATION;

ADULT; AFFECT; ANDROGENS; BONE DENSITY; CARDIOVASCULAR SYSTEM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIBIDO; MENOPAUSE; MIDDLE AGED; VASOMOTOR SYSTEM;

EID: 0033377591     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199912000-00016     Document Type: Conference Paper

References (57)

1. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80:1429-1430.
2. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: Altered profiles of steroid and pituitary hormones, SHBG, and bone mineral density. Maturitas. 1995;21:103-113.
3. Meldrum DR. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol.1981; 57:624-628.
4. Judd HL, Lucas WE, Yen SS. Effects of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol. 1974;118:793-798.
5. Endoh, A, Kristiansen SM, Casson PR, et al. The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex, resulting from its low expression of 3β-hydroxysteroid dehydrogenase. J Clin Endocrin Metab. 1996; 81:3558-3565.
6. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab. 1992;1002-1004.
7. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82:2396-2402.
8. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the perimenopausal years. Maturitas. 1986;8:189-196.
9. Longcope C, Jaffee W, Griffing G. Production rates of androgens and estrogens in postmenopausal women. Maturitas. 1981;3: 215-223.
10. Casson PR, Elkind-Hirsch K, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol. 1997;90:995-998.
11. McCoy NL, Davidson JM. A longitudinal study of the effects of menopausal on sexuality. Maturitas. 1985;7:203-210.
12. Sherwin BB, Gelfand M, Brender W. Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in surgical menopause. Psychosomatic Med. 1985;47:339-351.
13. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosomatic Med. 1987;49:397-409.
14. Myers LS, Dixon J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab. 1990;70:1124-1131.
15. Dennerstein L, Dudley EC, Hopper JL, Burger H. Sexuality, hormones, and the menopausal transition. Maturitas. 1997;26: 83-93.
16. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-236.
17. Tataryn IV, Lomax P, Meldrum DR, Bajorek JG, Chesarek W, Judd HL. Objective techniques for assessment of postmenopausal hot flashes. Obstet Gynecol. 1981; 57:340-344.
18. Kupperman HS, Blatt MHG, Weisbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab. 1953;13:668-703.
19. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with estradiol-testosterone implants: Clinical, lipid, and hormonal results. Maturitas. 1984;6:351-358.
20. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod P. Evaluation of an estrogen, androgen, estrogen-androgen, and placebo in the treatment of the menopause. J Clin Endocrinol Metab. 1950;10:1547-1558.
21. Simon JA, Kaiber E, Wiita B, Yang HM, Artis A, Ackerman DM. Double-blind comparison of estrogen-androgen combination and estrogen therapy in menopausal women: Effects on symptoms and neuroendocrine parameters (abstract). Fertil Steril. 1996;66S:71.
22. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529-537.
23. Sherwin BB, Gelfand MM. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flashes. Am J Obstet Gynecol. 1984;148: 552-557.
24. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985;151:153-160.
25. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988;14:177-187.
26. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab. 1996;81:37-43.
27. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78: 1360-1367.
28. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061.
29. Moroshima A, Grumbach MM, Simpson ER, Fischer C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiologic role of estrogens. J Clin Endocrinol Metab. 1995;80:3689-3698.
30. Erdtsieck RJ, Pols HAB, Van Kuijk C, et al. Course of bone mass during and after hormonal replacement therapy with and with addition of nandrolone decanoate. J Bone Miner Res. 1994;9:277-283.
31. Wild RA, Buchanan JR, Myers C, et al. Declining adrenal androgens: An association with bone loss in aging women. Proc Soc Exp Biol Med. 1987;186:355-360.
32. Spector TD, Thompson PW, Perry LA, et al. The relationship between sex steroids and bone mineral content in women soon after the menopause. Clin Endocrinol. 1991;34:37-41.
33. Barrett-Conner E, Kritz-Silverstein D, Edelstein SL. A prospective study of DS and bone mineral density in older men and women. Am J Epidemiol. 1993;137:201-206.
34. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Clin Endocrinol Metab. 1997;82:3498-3505.
35. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of 6-months treatment with a 100 mg daily dose of DHEA on circulating sex steroids, body composition, and muscle strength in age-advanced men and women. Clin Endocrinol. 1998;49(4):421-432.
36. Kuhn FE, Rackley CE. Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention. Arch Intern Med. 1993;153:2626-2636.
37. Ginsberg HN. Lipoprotein metabolism and its relationship to atherosclerosis. Med Clin North Am. 1994;78:1-20.
38. O'Brien KD, Chait A. The biology of the artery wall in atherogenesis. Med Clin North Am. 1994;78:41-67.
39. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravniker V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med. 1991;325: 1196-1204.
40. Reis SE, Gloth ST, Blumenthal RS, et al. Ethynyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
41. Stampfer MJ, Willet WC, Colditz GA, Rosner B, Speizer FE, Hennekins CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-1049.
42. Criqui MH, Suwarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined homogeneous community. Am J Epidemiology. 1988;128:606-614.
43. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312-317.
44. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoft E for the Heart and Estrogen/progestin Replacement Study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
45. LaRosa JC. Genetic and epidemiologic aspects of lipid metabolism. Am J Med. 1995; 98:1A-22S-1A-26S.
46. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary atherosclerosis and atherosclerosis related impairment of vascular response. Arterio Thromb Vasc Biol. 1995;15:562-570.
47. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol. 1993;82:919-924.
48. Sherwin BB, Gelfand MM, Schucher R, Gabor J. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. Am J Obstet Gynecol. 1987;152:414-419.
49. Wagner JD, Zhang L, Williams JK, et al. Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. Arterio Throm Vasc Biol. 1996;16:1473-1480.
50. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation. 1995;92:5-8.
51. Honore EK, Williams JK, Adams MR, Ackerman DM, Wagner JD. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity in cynomolgus monkeys. Menopause. 1996;3:20-26.
52. Sarrel PM, Wiita B. Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women. Fertil Steril. 1997; 68:1125-1127.
53. Katz S, Morales AJ. Dehydroepiandrosterone (DHEA) and DHEA-Sulfate (DS) as therapeutic options in menopause. Sem Reprod Endocrinol. 1998;16:161-170.
54. Diamond P, Cusan L, Gomez JL, et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996;150:S43-S50.
55. Barrett-Connor E, Timmons C, Young R, Wiita B, and the Estratest working group. Interim safety analysis of a 2-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Women Health. 1996;5: 593-602.
56. Gelfand MM, Wiita B. Androgen and estrogen-androgen replacement therapy: A review of the safety literature 1941-1996. Clin Ther. 1997;19:383-404.
57. Buckler HM, Robertson WR, Wu FCW. Which androgen replacement therapy for women? J Clin Endocrinol Metab. 1998;83: 3920-3924.